Abstract
The global threat of COVID-19 is still continued with no commercially
available vaccine or drug yet. While the application of convalescent
therapy is mostly beneficial, for critically ill patients, the
detrimental effect associated with some antibodies is also reported. The
immunoglobulin G (IgG) antibody in response to severe acute respiratory
syndrome coronavirus-2 (SARS-COV-2) infection is described, albeit the
lack of defining whether the difference in subclasses has a beneficial
or detrimental role. IgG2 has limited ability to activate innate immune
cells and complement-mediated inflammation, which has been described
inversely in SARS-COV-2 pathogenesis. The expansion of IgG2 is promoted
by interferon γ (IFN-γ), whereas there is a low level of IFN-γ in
COVID-19 patients. Therefore, this review describes the importance of
targeting IgG2, with IFN-γ in minimizing the SARS-COV-2 associated
inflammation, and may provide insight in the design of vaccine to
COVID-19.